Table 3
Summary of available epidemiologic data by outcome and country.
| | Total NHL | DLBCL and FL | Adult ALL | Pediatric ALL | MM | CLL |
| North and South America | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S |
| United States | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | Canada | ✓ | ✓ | ✓ | | | | ✓ | | ✓ | ✓
*
| | ✓
*
| ✓ | ✓ | ✓ | ✓ | | ✓ | Brazil | ✓ † | | | ✓ † | | | ✓ *† | | | ✓ *† | | | ✓ † | | | ✓ *† | | |
| European Union-5 | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S |
| United Kingdom | ✓ | ✓ | ✓ | ✓ | | | ✓ | | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | England | ✓ | ✓ | ✓ | ✓ † | | | ✓ | | | | | | ✓ | ✓ | ✓ | ✓ | | | Ireland | ✓ | | | ✓ | | | | | | | | | ✓ | | ✓ | | | | Republic of Ireland | ✓ | | ✓ | ✓ | | ✓ | ✓ | | ✓ | ✓ | | | ✓ | | ✓ | ✓ | | ✓ | Northern Ireland | ✓ | ✓ | ✓ | ✓ | | | ✓ | | ✓ | | | | ✓ | ✓ | ✓ | ✓ | | ✓ | Scotland | ✓ | ✓ | ✓ | | | | ✓ | ✓ | | | | | ✓ | ✓ | ✓ | ✓ | ✓ | | Wales | ✓ | ✓ | ✓ | | | | ✓ | ✓ | ✓ | ✓
*
| | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | France | ✓ | ✓ | ✓ † | | | | | | | ✓
*
| | ✓ | ✓ | ✓ | ✓ | ✓ | | | Germany | ✓ | ✓ | ✓ | ✓ † | | | ✓ † | | | ✓
*
| | ✓
*
| ✓ | | ✓ | ✓ † | | | Italy | ✓ | ✓ | ✓ | | | | ✓ | ✓ | ✓
*
| ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓
*
| Spain | ✓ | | ✓ † | | | | ✓ *† | | | ✓
*
| | ✓ | ✓ | | | ✓ *† | | |
| Asia | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S |
| China | ✓ | | ✓ † | | | | ✓
*
| | ✓ *† | ✓ *† | | | ✓ | | ✓ † | ✓
*
| | ✓ *† | Japan | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | South Korea | ✓ | ✓ | ✓ | | | | ✓
*
| ✓
*
| ✓ *† | ✓
*
| ✓
*
| | ✓ | ✓ | ✓ | ✓
*
| ✓
*
| ✓ *† | India | ✓ † | | ✓ † | | | | ✓ *† | | | ✓ *† | | ✓ *† | ✓ † | | | ✓ *† | | |
| Australia | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S | I | P | S |
| Australia | ✓ | | ✓ | ✓ | | | ✓ | | | ✓
*
| | ✓ | ✓ | | | ✓ | | |
|
|
ALL: acute lymphoblastic leukemia; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; I: incidence; MM: multiple myeloma; NHL: non-Hodgkin’s lymphoma; P: prevalence; S: survival.
*Data on lymphoid leukemia were used as a proxy for ALL and CLL. †Regional estimates were used a proxy for national estimates.
|